肿瘤免疫检查点抑制剂免疫相关不良反应影响因素及其与临床疗效关系的研究进展

Research progress on influencing factors of tumor immune-related adverse events and their relationship with clinical efficacy in tumor immune checkpoint inhibitors therapy

近年来,免疫治疗在多种肿瘤治疗中取得显著疗效,免疫治疗相关的单克隆抗体迅速发展,与此同时免疫相关不良反应也逐渐引起临床重视。多项研究发现免疫相关不良反应的发生可能与免疫检查点抑制剂疗效相关。药物类型、剂量、肿瘤类型、性别、联合用药、肠道微生物群、自身免疫性疾病史、一些生物标志物以及体质量指数、年龄、吸烟史、体力状况等个人风险因素、乙型或丙型肝炎病毒感染、一些常见基础疾病等都可能会影响免疫相关不良反应的严重程度。免疫治疗相关不良反应与疗效可能有一定的相关性,但似乎并不呈正相关,并且仅与部分不良反应有关。本文将报道肿瘤免疫检查点抑制剂治疗中免疫相关不良反应的影响因素及其与临床疗效关系的研究进展。

In recent years,immunotherapy has achieved remarkable efficacy in a variety of tumor treatments.Immunotherapy related monoclonal antibodies have developed rapidly.At the same time,Immune-related adverse events have gradually attracted clinical attention.Many studies have found that the occurrence of immune-related adverse events may be related to the efficacy of immune checkpoint inhibitors.Drug types,doses,tumor types,gender,immunotherapy combined therapy,gut microbiome,autoimmune diseases history,some biomarkers and some individual risk factors such as body mass index,age,smoking history,ECOG PS,hepatitis B or C virus infection,and some common pre-existing diseases may all affect the severity of immune-related adverse events.Immune-related adverse events of immunotherapy may be related to the efficacy,but it does not seem to be positive,and only related to some adverse events.This article will report the research progress on influencing factors of tumor immune-related adverse events and their relationship with clinical efficacy in tumor immune checkpoint inhibitors therapy.